MRK Jan 2022 95.000 call
| Previous close | 2.7700 |
| Open | 2.7100 |
| Bid | 2.5000 |
| Ask | 3.0500 |
| Strike | 95.00 |
| Expiry date | 2022-01-21 |
| Day's range | 2.7100 - 2.7100 |
| Contract range | N/A |
| Volume | 12 |
| Open interest | 485 |
- Yahoo Finance
Telehealth is going to 'become the default' for patients: Ro CEO
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
- Business Wire
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
LYNPARZA Approved by FDA for Treatment of HRR Gene-Mutated mCRPC That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
- Business Wire
CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
- Business Wire
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
- Zacks
Merck's (MRK) Keytruda Successful in Several Cancer Studies
Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.
- Motley Fool
Merck's Top Cancer Therapy Takes Another Big Leap Forward
Keytruda's path to becoming the world's top-selling drug looks much smoother following its latest clinical trial success.
- Reuters
Merck KGaA says profit could slip as fertility treatments shunned
Merck KGaA said a slight decline in operating earnings was on the cards this year as the coronavirus pandemic weighs on demand for chemicals in TV screens and is putting couples off seeking the German group's fertility treatments. First-quarter adjusted EBITDA gained 27% to 1.2 billion euros, the healthcare and chemicals company said, surpassing an average analyst estimate of 1.1 billion euros in a Refinitiv poll. Chinese patients sought larger prescriptions of Merck's older diabetes and heart drugs for less frequent hospital visits, offsetting lower sales of fertility drugs.
- Motley Fool
Merck Just Made a Gamble That Smart Investors Should Bet on Too
With increasing life expectancies and aging global populations comes higher prevalence of neurodegenerative disease. Merck is betting big on being the pharma company of the future.
- Business Wire
Merck to Present at the UBS Virtual Global Healthcare Conference
Merck to Present at the UBS Virtual Global Healthcare Conference
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
Merck's KEYTRUDA Superior to Brentuximab Vedotin , a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer
Merck’s KEYTRUDA Plus Chemotherapy Demonstrated Statistically Significant Improvement in PFS Versus Chemotherapy in Certain Patients with mTNBC
- Business Wire
New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
New Combination Data for Merck’s KEYTRUDA Demonstrated Clinical Benefit in Stage III NSCLC and Reinforce Long-Term Survival in Metastatic NSCLC
- Business Wire
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with VHL Disease-Associated Clear Cell Renal Cell Carcinoma
- Business Wire
Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
- Business Wire
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
- Business Wire
Merck Announces Virtual 2020 Annual Shareholders Meeting
Merck Announces Virtual 2020 Annual Shareholders Meeting
- Simply Wall St.
Is Merck & Co., Inc.'s (NYSE:MRK) CEO Paid At A Competitive Rate?
In 2011, Ken Frazier was appointed CEO of Merck & Co., Inc. (NYSE:MRK). This report will, first, examine the CEO...
- Business Wire
Merck to Present at the BofA Securities 2020 Health Care Conference
Merck to Present at the BofA Securities 2020 Health Care Conference
- Business Wire
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
- Motley Fool
2 Beaten-Down Stocks to Buy Right Now
With earnings season in full gear, we are now starting to see the effects of the outbreak on the financial results of corporations. Among the many companies that expect the public health crisis to hurt their financial results are Merck (NYSE: MRK) and Medtronic (NYSE: MDT). Year to date, shares of Merck have slid by 15.3%, while Medtronic's stock is down by 14.7% over the same period, which means both companies have performed even worse than the broader market.
- Yahoo Finance
Express Scripts' 'Parachute' to cap prescription costs for those hit by coronavirus turmoil
Cigna’s (CI) Express Scripts is offering a new prescription drug program that limits costs to consumers, acting as a safety net for millions of newly uninsured individuals.
- Reuters - UK Focus
Cigna's Express Scripts offers discounted drugs for U.S. newly unemployed
Express Scripts is offering discounted $25 and $75 prescription drug prices to the newly uninsured, a stop-gap measure aimed at Americans who lose their jobs and health insurance due to the coronavirus pandemic. The U.S. pharmacy benefit manager owned by Cigna Corp said the offer included thousands of generic drugs, which would be priced at $25 and branded medications priced at $75. Express said the offer, which is temporary, includes drugs for asthma, diabetes drug, glaucoma, heart disease, migraine, reproductive health, seizures and thyroid conditions.
- Business Wire
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP
- Business Wire
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
- Motley Fool
Did Merck Just Receive a Gift From the FDA?
Receiving a diagnosis of cancer is scary. Undergoing treatment to fight the cancer can be just as frightening. Luckily, a new treatment regimen for certain types of cancer may halve the number of patient visits to the clinic for therapy.
